CoChat

Pasireotide—a novel somatostatin receptor ligand after 20 years of use

Open access
Bolanowski, Marek, Kałużny, Marcin, Witek, Przemysław, Jawiarczyk-Przybyłowska, Aleksandra · 2022 · Reviews in Endocrine and Metabolic Disorders
Cited by 66

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Pasireotide, a novel multireceptor-targeted somatostatin receptor ligand (SRL) is characterized by a higher affinity to somatostatin receptor type 5 than type 2, unlike first-generation SRLs. Because of the broader binding profile, pasireotide has been suggested to have a greater clinical efficacy in acromegaly than first-generation SRLs and to be efficacious in Cushing’s disease. The consequence of this binding profile is the increased blood glucose level in some patients. This results from the inhibition of both insulin secretion and the incretin effect and only a modest suppression of glucagon. A monthly intramuscular formulation of long-acting release pasireotide has been approved for both acromegaly and Cushing’s disease treatment. This review presents data on the efficacy and safety of pasireotide treatment mostly in patients with acromegaly and Cushing’s disease. Moreover, other possible therapeutic applications of pasireotide are mentioned.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s11154-022-09710-3

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 66

Metadata

Authors
Bolanowski, M., Kałużny, M., Witek, P., & Jawiarczyk-Przybyłowska, A.
Venue
Reviews in Endocrine and Metabolic Disorders
Published
2022-01-24
Volume
23
Issue
3
Pages
601-620
ISSN
  • 1389-9155 (ISSN-L)
  • 1573-2606
OpenAlex
W4206989655
Cited by
66
References
6
FWCI
8.28
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pasireotide—a novel somatostatin receptor ligand after 20 years of use. https://app.cochat.ai/papers/10.1007/s11154-022-09710-3
The paper
Bolanowski, M., Kałużny, M., Witek, P., & Jawiarczyk-Przybyłowska, A. (2022). Pasireotide—a novel somatostatin receptor ligand after 20 years of use. Reviews in Endocrine and Metabolic Disorders. https://doi.org/10.1007/s11154-022-09710-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.